All Stories

  1. Development of rhesus macaque astrocyte cell lines supporting infection with a panel of viruses
  2. Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage
  3. The Inhibition of Gag-Pol Expression by the Restriction Factor Shiftless Is Dispensable for the Restriction of HIV-1 Infection
  4. Diversification of the VH3‐53 immunoglobulin gene segment by somatic hypermutation results in neutralization of SARS‐CoV‐2 virus variants
  5. Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany
  6. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency
  7. Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
  8. Development of immortalized rhesus macaque kidney cells supporting infection with a panel of viruses
  9. Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
  10. TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
  11. Primate Simplexviruses Differ in Tropism for Macaque Cells
  12. Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19
  13. The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
  14. Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
  15. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
  16. Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment
  17. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
  18. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
  19. Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of −1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruse...
  20. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
  21. Mutagenic Analysis of the HIV Restriction Factor Shiftless
  22. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
  23. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination
  24. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
  25. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
  26. Understanding Omicron: Transmissibility, immune evasion and antiviral intervention
  27. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
  28. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
  29. Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract
  30. Omicron: Master of immune evasion maintains robust ACE2 binding
  31. Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein
  32. Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
  33. Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination
  34. Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review
  35. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
  36. Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases
  37. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
  38. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2
  39. A Recombinant System and Reporter Viruses for Papiine Alphaherpesvirus 2
  40. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses
  41. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
  42. Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies
  43. Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1
  44. Erythrocytes increase endogenous sphingosine 1-phosphate levels as an adaptive response to SARS-CoV-2 infection
  45. Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease
  46. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
  47. Spike residue 403 affects binding of coronavirus spikes to human ACE2
  48. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
  49. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity
  50. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
  51. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
  52. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
  53. The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection
  54. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model
  55. Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5
  56. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
  57. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
  58. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
  59. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
  60. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
  61. How SARS-CoV-2 makes the cut
  62. Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
  63. Urinary Levels of SARS-CoV-2 Nucleocapsid Protein Associate With Risk of AKI and COVID-19 Severity: A Single-Center Observational Study
  64. Therapeutic Application of alpha-1-antitrypsin in COVID-19
  65. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles
  66. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
  67. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
  68. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection
  69. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
  70. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
  71. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
  72. Mutation D614G increases SARS-CoV-2 transmission
  73. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
  74. Dalbavancin: novel candidate for COVID-19 treatment
  75. Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling
  76. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
  77. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
  78. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties
  79. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
  80. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
  81. Corrigendum: Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein–Ligand Interactions
  82. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
  83. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells
  84. Sphingosine prevents binding of SARS–CoV-2 spike to its cellular receptor ACE2
  85. Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin–Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly
  86. LY6E impairs coronavirus fusion and confers immune control of viral disease
  87. Chloroquine does not inhibit SARS-CoV-2
  88. Probing Multivalent Lectin-Carbohydrate Binding via Multifunctional Glycan-Gold Nanoparticles: Implications for Blocking Virus Infection
  89. Probing Multivalent Lectin-Carbohydrate Binding via Multifunctional Glycan-Gold Nanoparticles: Implications for Blocking Virus Infection
  90. Furin cleavage of SARS-CoV-2 spike is required for infection of lung cells
  91. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
  92. H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice
  93. Nafamostat inhibits SARS-CoV-2
  94. SARS-CoV-2 uses ACE2 and TMPRSS2 for infection of lung cells
  95. SARS-CoV-2 uses ACE2 and TMPRSS2 for infection of lung cells
  96. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus
  97. A Fosmid-Based System for the Generation of Recombinant Cercopithecine Alphaherpesvirus 2 Encoding Reporter Genes
  98. Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques
  99. Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins
  100. Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways
  101. Spike proteins of novel MERS-coronavirus isolates from North- and West-African dromedary camels mediate robust viral entry into human target cells
  102. Evidence for influenza B virus hemagglutinin adaptation to the human host: high cleavability, acid-stability and preference for cool temperature
  103. Analysis of IFITM-IFITM Interactions by a Flow Cytometry-Based FRET Assay
  104. Kaposi sarcoma in a guereza monkey
  105. Novel Virus Related to Kaposi’s Sarcoma–Associated Herpesvirus from Colobus Monkey
  106. Evidence that Calu-3 cells are largely resistant to Ebola virus entry
  107. Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis
  108. IFITM s mediate viral evasion in acute and chronic hepatitis C virus infection
  109. Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins
  110. SPP and SKI-1 inhibitor block Ebola virus entry
  111. Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance
  112. Detection of antibodies against viruses in a macaque colony using a chip-based approach
  113. The cell Line SH-SY5Y is resistant to infection by Ebola virus and other filoviruses
  114. A safe system for production of defective interfering particles
  115. Virosomes interfere with Ebola virus control by the immune system
  116. Focal epithelial hyperplasia and papillomavirus infection in a bonobo
  117. Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies
  118. Tetherin efficiently inhibits Nipah virus but not Ebola virus spread in fruit bat cells
  119. MERS-coronavirus spike protein: Importance of protease cleavage sites for viral entry
  120. A MERS-coronavirus variant that is partially resistant against neutralizing antibodies
  121. The cellular protease TMPRSS11A can convert influenza virus into an infectious form
  122. Cell Entry of Influenza A Viruses: Sweet Talk between HA and Ca V 1.2
  123. A GXXXA motif in the Ebola virus glycoprotein is required for tetherin antagonism
  124. Attachment/Binding
  125. VSV-G antagonizes tetherin in transfected cells
  126. Inhibition of lectin-dependent enhancement of Ebola virus entry into cells
  127. Identification of sites in SARS-S required cleavage and activation by TMPRSS2
  128. TMPRSS2 of non-human primates activates influenza viruses
  129. Herpes B virus replication and viral lesions in the liver of a cynomolgus macaque which died from severe disease with rapid onset
  130. pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs
  131. Rhesus macaque IFITM3 gene polymorphisms and SIV infection
  132. A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry
  133. Detection systems for antibody responses against herpes B virus
  134. Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide
  135. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins
  136. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies
  137. The Role of Phlebovirus Glycoproteins in Viral Entry, Assembly and Release
  138. The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells
  139. Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions
  140. Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions
  141. The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent
  142. The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases
  143. TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells
  144. Exclusive Decoration of Simian Immunodeficiency Virus Env with High-Mannose Type N-Glycans Is Not Compatible with Mucosal Transmission in Rhesus Macaques
  145. Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase
  146. Interferon-Induced Transmembrane Protein–Mediated Inhibition of Host Cell Entry of Ebolaviruses
  147. Analysis of Ebola Virus Entry Into Macrophages
  148. Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976
  149. Protease inhibitors targeting coronavirus and filovirus entry
  150. IFITM Proteins Inhibit Entry Driven by the MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms
  151. DESC1 and MSPL Activate Influenza A Viruses and Emerging Coronaviruses for Host Cell Entry
  152. Inhibition of Proprotein Convertases Abrogates Processing of the Middle Eastern Respiratory Syndrome Coronavirus Spike Protein in Infected Cells but Does Not Reduce Viral Infectivity
  153. Bitter-sweet symphony: glycan–lectin interactions in virus biology
  154. Influenza A Virus Encoding Secreted Gaussia Luciferase as Useful Tool to Analyze Viral Replication and Its Inhibition by Antiviral Compounds and Cellular Proteins
  155. Analysis of Determinants in Filovirus Glycoproteins Required for Tetherin Antagonism
  156. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry
  157. Induced and spontaneous heart rate turbulence in mice: influence of coupling interval
  158. Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4+ T Cells
  159. Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice
  160. Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
  161. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research
  162. TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein
  163. Platelet activation suppresses HIV-1 infection of T cells
  164. TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium
  165. The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies
  166. Severe Fever with Thrombocytopenia Virus Glycoproteins Are Targeted by Neutralizing Antibodies and Can Use DC-SIGN as a Receptor for pH-Dependent Entry into Human and Animal Cell Lines
  167. Cellular Entry of Retroviruses
  168. Attachment/Binding
  169. Host Cell Factors in Filovirus Entry: Novel Players, New Insights
  170. The role of the alternative coreceptor GPR15 in SIV tropism for human cells
  171. How Ebola Virus Counters the Interferon System
  172. Influenza A Virus Does Not Encode a Tetherin Antagonist with Vpu-Like Activity and Induces IFN-Dependent Tetherin Expression in Infected Cells
  173. Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts
  174. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression
  175. CD4- and dynamin-dependent endocytosis of HIV-1 into plasmacytoid dendritic cells
  176. Comparative Analysis of Ebola Virus Glycoprotein Interactions With Human and Bat Cells
  177. The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin
  178. The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors
  179. Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease
  180. DC-SIGN: Access Portal for Sweet Viral Killers
  181. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion
  182. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
  183. Mouse LSECtin as a model for a human Ebola virus receptor
  184. The multiple facets of HIV attachment to dendritic cell lectins
  185. Novel insights into proteolytic cleavage of influenza virus hemagglutinin
  186. TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells
  187. A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms
  188. Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2
  189. Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion Proteins
  190. Calcium-modulating cyclophilin ligand does not restrict retrovirus release
  191. Lectin-like interactions in virus–cell recognition
  192. Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63
  193. Cellular Entry of the SARS Coronavirus: Implications for Transmission, Pathogenicity and Antiviral Strategies
  194. Type II transmembrane serine proteases in cancer and viral infections
  195. Proteolytic Activation of the 1918 Influenza Virus Hemagglutinin
  196. Carbohydrates on HIV: mediators of immune evasion and targets for antiviral intervention
  197. Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding
  198. Analysis of the Interaction of Ebola Virus Glycoprotein with DC‐SIGN (Dendritic Cell–Specific Intercellular Adhesion Molecule 3–Grabbing Nonintegrin) and Its Homologue DC‐SIGNR
  199. A Novel Mechanism for LSECtin Binding to Ebola Virus Surface Glycoprotein through Truncated Glycans
  200. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin
  201. Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
  202. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo
  203. The C-type Lectin Receptors CLEC-2 and Dectin-1, but Not DC-SIGN, Signal via a Novel YXXL-dependent Signaling Cascade
  204. Attachment of human immunodeficiency virus to cells and its inhibition
  205. DC-SIGN and CLEC-2 Mediate Human Immunodeficiency Virus Type 1 Capture by Platelets
  206. Modulation of virion incorporation of Ebolavirus glycoprotein: Effects on attachment, cellular entry and neutralization
  207. Highly Conserved Regions within the Spike Proteins of Human Coronaviruses 229E and NL63 Determine Recognition of Their Respective Cellular Receptors
  208. The Signal Peptide of the Ebolavirus Glycoprotein Influences Interaction with the Cellular Lectins DC-SIGN and DC-SIGNR
  209. Cellular Entry of HIV: Evaluation of Therapeutic Targets
  210. Impact of polymorphisms in the DC-SIGNR neck domain on the interaction with pathogens
  211. Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN
  212. Evidence that multiple defects in murine DC-SIGN inhibit a functional interaction with pathogens
  213. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2
  214. Interaction Between the Spike Protein of Human Coronavirus NL63 and its Cellular Receptor ACE2
  215. Attachment Factor and Receptor Engagement of Sars Coronavirus and Human Coronavirus NL63
  216. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus
  217. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
  218. DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus
  219. Cellular entry of the SARS coronavirus
  220. Differential regulation of human immunodeficiency virus type 2 and simian immunodeficiency virus promoter activity
  221. Prospects of HIV‐1 entry inhibitors as novel therapeutics
  222. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor
  223. S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients
  224. Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors
  225. Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency
  226. Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
  227. Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR
  228. DC-SIGN and DC-SIGNR Bind Ebola Glycoproteins and Enhance Infection of Macrophages and Endothelial Cells
  229. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
  230. Diversity of receptors binding HIV on dendritic cell subsets
  231. Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells
  232. The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination?
  233. Hemofiltrate CC Chemokine 1[9-74] Causes Effective Internalization of CCR5 and Is a Potent Inhibitor of R5-Tropic Human Immunodeficiency Virus Type 1 Strains in Primary T Cells and Macrophages
  234. CD4 Independence of Simian Immunodeficiency Virus Envs Is Associated with Macrophage Tropism, Neutralization Sensitivity, and Attenuated Pathogenicity
  235. Evaluation of Current Approaches to Inhibit HIV Entry
  236. Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques
  237. DC-SIGN and DC-SIGNR: helping hands for HIV
  238. Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN
  239. DC-SIGN Interactions with Human Immunodeficiency Virus: Virus Binding and Transfer Are Dissociable Functions
  240. Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV
  241. The Role of DC-SIGN and DC-SIGNR in HIV and SIV Attachment, Infection, and Transmission
  242. Basic Amino Acid Residues in the V3 Loop of Simian Immunodeficiency Virus Envelope Alter Viral Coreceptor Tropism and Infectivity but Do Not Allow Efficient Utilization of CXCR4 as Entry Cofactor
  243. DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus
  244. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans
  245. Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties
  246. Simian Immunodeficiency Virus Utilizes Human and Sooty Mangabey but Not Rhesus Macaque STRL33 for Efficient Entry
  247. Co‐receptor Usage of BOB/GPR15 in Addition to CCR5 Has No Significant Effect on Replication of Simian Immunodeficiency Virus In Vivo